JP2023534923A5 - - Google Patents
Info
- Publication number
- JP2023534923A5 JP2023534923A5 JP2023500329A JP2023500329A JP2023534923A5 JP 2023534923 A5 JP2023534923 A5 JP 2023534923A5 JP 2023500329 A JP2023500329 A JP 2023500329A JP 2023500329 A JP2023500329 A JP 2023500329A JP 2023534923 A5 JP2023534923 A5 JP 2023534923A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- polypeptide
- polypeptide according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063048589P | 2020-07-06 | 2020-07-06 | |
| US63/048,589 | 2020-07-06 | ||
| US202063070035P | 2020-08-25 | 2020-08-25 | |
| US63/070,035 | 2020-08-25 | ||
| PCT/US2021/040546 WO2022010921A1 (en) | 2020-07-06 | 2021-07-06 | Antigen binding molecules targeting sars-cov-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534923A JP2023534923A (ja) | 2023-08-15 |
| JP2023534923A5 true JP2023534923A5 (cg-RX-API-DMAC7.html) | 2024-07-17 |
Family
ID=77127097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500329A Pending JP2023534923A (ja) | 2020-07-06 | 2021-07-06 | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11981725B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4175983A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534923A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230035350A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021306709A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183367A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299630A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022010921A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| WO2023173577A1 (zh) * | 2022-03-15 | 2023-09-21 | 慧壹科技(上海)有限公司 | 冠状病毒抗体及其用途 |
| EP4519310A1 (en) | 2022-05-06 | 2025-03-12 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| WO2024102674A1 (en) | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG128680A1 (en) * | 2003-07-22 | 2007-01-30 | Crucell Holland Bv | Binding molecules against sars-coronavirus and uses thereof |
| CA2548942C (en) | 2003-12-05 | 2013-10-15 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
| US8106170B2 (en) * | 2004-11-11 | 2012-01-31 | Crucell Holland B.V. | Compositions against SARS-coronavirus and uses thereof |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| UA119328C2 (uk) | 2013-08-09 | 2019-06-10 | Астеллас Фарма Інк. | Антитіло до тslp-рецептора людини |
| CN108064243B (zh) | 2014-10-01 | 2021-08-27 | 免疫医疗有限公司 | 对lox1具有特异性的结合蛋白及其用途 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| WO2020180398A1 (en) | 2019-01-14 | 2020-09-10 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| JP2023512684A (ja) | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| EP4121454A1 (en) * | 2020-03-19 | 2023-01-25 | Imperial College Innovations Limited | Coronavirus antibody |
| US11028167B1 (en) | 2020-03-23 | 2021-06-08 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 3bgf |
| KR20250107297A (ko) | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| US20230348571A1 (en) | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| JP2023521418A (ja) | 2020-04-10 | 2023-05-24 | インビビド， インコーポレイテッド | コロナウイルスｓタンパク質に特異的な化合物及びその使用 |
| US20240059757A1 (en) | 2020-04-14 | 2024-02-22 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| US20230174628A1 (en) | 2020-04-28 | 2023-06-08 | Peking University | Anti-novel coronavirus monoclonal antibody and application thereof |
| WO2021226560A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| WO2022015573A2 (en) | 2020-07-13 | 2022-01-20 | President And Fellows Of Harvard College | Sars-cov-2 antigen-binding proteins and uses thereof |
| WO2022026475A2 (en) | 2020-07-27 | 2022-02-03 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022046888A1 (en) | 2020-08-25 | 2022-03-03 | Target Discovery Merger Sub II, LLC | Sars-cov-2 associated antibody compositions and methods of use |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| KR20230127305A (ko) | 2020-12-29 | 2023-08-31 | 발-첨, 리미티드 파트너십 | Covid-19에 대한 중화 단일클론 항체 |
| WO2022159685A2 (en) | 2021-01-22 | 2022-07-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| KR20240035758A (ko) | 2021-05-24 | 2024-03-18 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 폴리펩타이드 |
| WO2022271863A1 (en) | 2021-06-23 | 2022-12-29 | Chan Zuckerberg Biohub, Inc. | Coronavirus neutralizing compositions and associated methods |
| WO2023028603A2 (en) | 2021-08-27 | 2023-03-02 | Humabs Biomed Sa | Engineered compositions |
| EP4147716A1 (en) | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| EP4519310A1 (en) | 2022-05-06 | 2025-03-12 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
-
2021
- 2021-07-06 CA CA3183367A patent/CA3183367A1/en active Pending
- 2021-07-06 AU AU2021306709A patent/AU2021306709A1/en active Pending
- 2021-07-06 JP JP2023500329A patent/JP2023534923A/ja active Pending
- 2021-07-06 WO PCT/US2021/040546 patent/WO2022010921A1/en not_active Ceased
- 2021-07-06 IL IL299630A patent/IL299630A/en unknown
- 2021-07-06 EP EP21748743.8A patent/EP4175983A1/en active Pending
- 2021-07-06 KR KR1020237003926A patent/KR20230035350A/ko active Pending
-
2023
- 2023-01-06 US US18/151,194 patent/US11981725B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534923A5 (cg-RX-API-DMAC7.html) | ||
| JP2023540037A5 (cg-RX-API-DMAC7.html) | ||
| JP2023534922A5 (cg-RX-API-DMAC7.html) | ||
| CN108026166B (zh) | 多瘤病毒中和抗体 | |
| US8273354B2 (en) | Anti-RSV G protein antibodies | |
| US10016496B2 (en) | Respiratory syncytial virus F protein epitopes | |
| US20240336672A1 (en) | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof | |
| US11248039B2 (en) | Immunoglobulin single variable domain antibody against RSV prefusion F protein | |
| CN116528897A (zh) | 靶向SARS-CoV-2的抗原结合分子 | |
| JP2023534923A (ja) | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 | |
| JP2023534922A (ja) | ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 | |
| JP2009524428A5 (cg-RX-API-DMAC7.html) | ||
| WO2014115893A1 (ja) | ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片 | |
| JP2025537301A (ja) | Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 | |
| US20220340658A1 (en) | NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF | |
| Addetia et al. | Potent neutralization of Marburg virus by a vaccine-elicited antibody | |
| WO2023148641A1 (en) | Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof | |
| CN113549146B (zh) | 针对柯萨奇病毒b1型的单克隆抗体及其用途 | |
| CN119638829B (zh) | 抗pspb抗体及其应用 | |
| US20240043506A1 (en) | Sars-cov-2 antibodies | |
| US20220227843A1 (en) | Coronavirus-binding molecules and methods of use thereof | |
| CN116547005A (zh) | 靶向SARS-CoV-2的抗原结合分子 | |
| CN117982437A (zh) | 一种靶向冠状病毒的抗体制剂及其应用 | |
| CN116514965A (zh) | 甲型肝炎病毒抗体及其应用 | |
| WO2022074621A1 (en) | Covid-19-binding immunoglobulins and methods for their use |